Irina Fernandez
Overview
Explore the profile of Irina Fernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
775
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jacobsen G, Gonzalez E, Mendygral P, Faust K, Hazime H, Fernandez I, et al.
Inflamm Bowel Dis
. 2025 Feb;
PMID: 39951038
Background: Crohn's disease (CD) is characterized by an inflammatory response to gut microbiota. Macrophages and dendritic cells play an active role in CD inflammation. Specific microbiota have been implicated in...
2.
Mortera S, Marzano V, Rapisarda F, Marangelo C, Pirona I, Vernocchi P, et al.
Microbiome
. 2024 Oct;
12(1):217.
PMID: 39443987
Background: Crohn's disease (CD) is characterized by chronic intestinal inflammation. Diet is a key modifiable factor influencing the gut microbiome (GM) and a risk factor for CD. However, the impact...
3.
Intestinal Epithelial Inactivity of Dual Oxidase 2 Results in Microbiome-Mediated Metabolic Syndrome
Hazime H, Ducasa G, Santander A, Brito N, Gonzalez E, Ban Y, et al.
Cell Mol Gastroenterol Hepatol
. 2023 Jun;
16(4):557-572.
PMID: 37369278
Background & Aims: Metabolic syndrome (MetS) is characterized by obesity, glucose intolerance, and hepatic steatosis. Alterations in the gut microbiome play important roles in the development of MetS. However, the...
4.
Jacobsen G, Fernandez I, Quintero M, Santander A, Pignac-Kobinger J, Damas O, et al.
Gastro Hep Adv
. 2022 Sep;
1(3):380-392.
PMID: 36061955
Background And Aims: Lamina propria phagocytes are key mediators of inflammatory bowel disease (IBD). We aimed to understand the transcriptomic and functional differences in these cells based on location, disease...
5.
Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy
Abreu M, Davies J, Quintero M, Delmas A, Diaz S, Martinez C, et al.
Inflamm Bowel Dis
. 2022 Aug;
28(12):1800-1812.
PMID: 35993552
Background: Inflammatory bowel disease (IBD) involves chronic T cell-mediated inflammatory responses. Vedolizumab (VDZ), a monoclonal antibody against α4β7 integrin, inhibits lymphocyte extravasation into intestinal mucosae and is effective in ulcerative...
6.
Berera S, Ioannou S, Morillo D, Mantero A, Pignac-Kobinger J, Colina N, et al.
J Crohns Colitis
. 2022 Jun;
16(11):1687-1695.
PMID: 35642747
Background And Aims: The efficacy of current biologics may be limited by targeting only one pathway. Pentoxifylline [PTX] interferes with tumour necrosis factor [TNF] gene expression. We performed a randomised,...
7.
Burgueno J, Fritsch J, Gonzalez E, Landau K, Santander A, Fernandez I, et al.
Gastroenterology
. 2020 Oct;
160(3):797-808.e6.
PMID: 33127391
Background & Aims: Chronic colonic inflammation leads to dysplasia and cancer in patients with inflammatory bowel disease. We have described the critical role of innate immune signaling via Toll-like receptor...
8.
Fritsch J, Garces L, Quintero M, Pignac-Kobinger J, Santander A, Fernandez I, et al.
Clin Gastroenterol Hepatol
. 2020 May;
19(6):1189-1199.e30.
PMID: 32445952
Background & Aims: A high-fat diet has been associated with an increased risk of ulcerative colitis (UC). We studied the effects of a low-fat, high-fiber diet (LFD) vs an improved...
9.
Burgueno J, Reich A, Hazime H, Quintero M, Fernandez I, Fritsch J, et al.
Inflamm Bowel Dis
. 2020 Apr;
26(6):797-808.
PMID: 32333601
Background: Patients with inflammatory bowel disease (IBD) have intestinal inflammation and are treated with immune-modulating medications. In the face of the coronavirus disease-19 pandemic, we do not know whether patients...
10.
Goswami S, Walle T, Cornish A, Basu S, Anandhan S, Fernandez I, et al.
Nat Med
. 2019 Dec;
26(1):39-46.
PMID: 31873309
Immune checkpoint therapy with anti-CTLA-4 and anti-PD-1/PD-L1 has revolutionized the treatment of many solid tumors. However, the clinical efficacy of immune checkpoint therapy is limited to a subset of patients...